RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the localized treatment of solid tumors and conducting a Phase 3 registration trial for our lead product candidate, RenovoGem. Our therapeutic platform, RenovoRx Trans-Arterial Micro-Perfusion or RenovoTAMP, utilizes approved chemotherapy drugs with proven mechanisms of action and well-established safety and side effect profiles, aiming to enhance their efficacy, improve their safety, and expand their therapeutic window. RenovoTAMP combines our patented FDA-cleared delivery system, RenovoCath, with chemotherapy agents, which use pressure to force these anti-cancer drugs to locally target the blood vessel walls of solid tumors.